Mutual of America Capital Management LLC Lowers Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Mutual of America Capital Management LLC reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 27.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 202,654 shares of the specialty pharmaceutical company’s stock after selling 75,782 shares during the period. Mutual of America Capital Management LLC’s holdings in Supernus Pharmaceuticals were worth $6,319,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Armistice Capital LLC boosted its stake in Supernus Pharmaceuticals by 47.6% during the second quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company’s stock valued at $141,026,000 after buying an additional 1,700,000 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Supernus Pharmaceuticals by 12.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock valued at $76,690,000 after acquiring an additional 309,966 shares during the last quarter. Stephens Investment Management Group LLC grew its holdings in shares of Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after purchasing an additional 33,710 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Supernus Pharmaceuticals by 26.4% in the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock worth $45,077,000 after purchasing an additional 351,900 shares during the last quarter. Finally, Pacer Advisors Inc. raised its stake in Supernus Pharmaceuticals by 100,186.3% in the second quarter. Pacer Advisors Inc. now owns 1,349,854 shares of the specialty pharmaceutical company’s stock valued at $36,109,000 after purchasing an additional 1,348,508 shares in the last quarter.

Insider Activity

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 14,213 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total value of $520,480.06. Following the completion of the sale, the director now owns 13,315 shares in the company, valued at approximately $487,595.30. The trade was a 51.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jack A. Khattar sold 125,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the transaction, the chief executive officer now owns 926,172 shares in the company, valued at $33,971,988.96. This represents a 11.89 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 154,213 shares of company stock valued at $5,660,180. 9.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $35.53 on Wednesday. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $39.37. The stock has a 50 day simple moving average of $33.42 and a two-hundred day simple moving average of $30.99. The firm has a market cap of $1.96 billion, a P/E ratio of 33.21 and a beta of 0.86.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm’s revenue was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.29) EPS. On average, equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.